PDCD1 and neoplasm: In preclinical studies, although TIGIT inhibition alone had minimal effects on tumor growth, the dual blockade of PD-1 and TIGIT acted synergistically to overcome resistance mechanisms to anti-PD-(L)1 therapy [91].